Services
The facility's aim is to provide internal and external users a broad range of services based on its long-standing and diverse expertise in the development, manufacture and therapeutic use of advanced-therapy medicinal products (ATMP) and tissue engineering products (TEP) and their regulatory drug approval.
The core facility "Good Manufacturing Practice Biomedical Campus Dresden“ (GMPBD) consists of 5 GMP units which are mainly located on the university hospital campus. Part of this GMP cluster are cleanrooms at the Medical Clinics I (hematopoietic stem cells / cell therapy products) and the Medical Clinics III (islet transplantation program), at the Center for Regenerative Therapies (stem cell therapies), the Max Bergmann Centre of Biomaterials and the German Red Cross (blood / blood products). The GMP core offers a unique infrastructure for applied biomedical research: GMP-conform production sites with state-of-the-art equipment as well as medico-legal competence.
Due to the long lasting, sound expertise within this cluster we were already able to implement standard operating procedures (SOPs) for the generation of GMP-grade Mesenchymal Stromal Cells (MSC), regulatory T-lymphocytes (Treg) and islet cells.
The latest addition to the portfolio is the generation of autologous, stemcell-based matrix-associated chondrocyte transplants (MSC-MACT) for the potential treatment of focal lesions of the cartilage of the knee.
Implemented protocols and cell types
| Cell type | Application |
| allogeneic Mesenchymal stromal cells from bone marrow (BM-MSC) and umbilical cord (UC-MSC) | - Graft-versus-Host-Disease (GvHD) - Morbus Crohn |
| autologous Mesenchymal stromal cells from bone marrow (BM-MSC) | - bone remodelling - cartilage remodelling - macula degeneration and diabetic retinopathy |
| Regulatory T-lymphocytes (Treg) | - autoimmune diseases |
| virus-specific T-lymphocytes | - transplantation-associated viral infections |
| autologous Islet cells | - type 1 Diabetes mellitus |